Comparing the current results to its competitors, Uniqure N V reported Revenue increase in the 1 quarter 2026 by 127.31 % year on year. The sales growth was above Uniqure N V 's competitors' average revenue growth of 4.09 %, achieved in the same quarter.
Uniqure N v , slower than the average decrease reported by the company's competitors of -10.52 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -10.52 %
In a recent development, uniQure, a leading gene therapy company, has announced the FDA clearance of their Investigational New Drug Application (IND) for AMT-191 gene therapy for Fabry Disease. This news is expected to pave the way for patient enrollment, set to begin in the first half of 2024. Fabry Disease is a rare genetic disorder that affects the body s ability to break down a certain type of fat. uniQure s AMT-191 gene therapy aims to address this by introducing a corrective gene into the patient s cells to restore the enzyme activity and alleviate the symptoms associated with the disease. The FDA clearance signifies a significant step forward in the development of this potentially life-chang...
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.
is a global software and services company that enables industrial companies to improve growth with a portfolio of innovative digital solutions that work together to transform how physical products are engineered, manufactured, and serviced
PTC Therapeutics Inc's business model revolves around the research, development, and commercialization of innovative treatments for rare and genetic diseases.
Sources:
Uniqure N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Uniqure N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
